Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Simple item page
dc.contributor.authorErol C.
dc.contributor.authorSendur M.A.N.
dc.contributor.authorBilgetekin I.
dc.contributor.authorGarbioglu D.B.
dc.contributor.authorHamdard J.
dc.contributor.authorAkbas S.
dc.contributor.authorHizal M.
dc.contributor.authorArslan C.
dc.contributor.authorSevinc A.
dc.contributor.authorKucukarda A.
dc.contributor.authorErdem D.
dc.contributor.authorKahraman S.
dc.contributor.authorCakir E.
dc.contributor.authorDemirkiran A.
dc.contributor.authorOn S.
dc.contributor.authorDogan I.
dc.contributor.authorErdogan A.P.
dc.contributor.authorKoca S.
dc.contributor.authorKubilay P.
dc.contributor.authorEren O.O.
dc.contributor.authorCilbir E.
dc.contributor.authorCelik E.
dc.contributor.authorAraz M.
dc.contributor.authorOzyukseler D.T.
dc.contributor.authorYildirim M.E.
dc.contributor.authorBahceci A.
dc.contributor.authorTaskaynatan H.
dc.contributor.authorOyman A.
dc.contributor.authorDeniz G.I.
dc.contributor.authorMenekse S.
dc.contributor.authorKut E.
dc.contributor.authorGulmez A.
dc.contributor.authorSakin A.
dc.contributor.authorNayir E.
dc.contributor.authorAcar R.
dc.contributor.authorSen E.
dc.contributor.authorInal A.
dc.contributor.authorTurhal S.
dc.contributor.authorKaya A.O.
dc.contributor.authorPaydas S.
dc.contributor.authorTastekin D.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorCincin I.
dc.contributor.authorBilici A.
dc.contributor.authorMandel N.M.
dc.contributor.authorDede D.S.
dc.contributor.authorAkinci M.B.
dc.contributor.authorOksuzoglu B.
dc.contributor.authorUncu D.
dc.contributor.authorYalcin B.
dc.contributor.authorArtac1 M.
dc.date.accessioned2024-07-22T08:03:48Z
dc.date.available2024-07-22T08:03:48Z
dc.date.issued2022
dc.description.abstractAims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in patients with metastatic CRC in real-life experience. Materials and Methods: Four hundred and thirty-three patients who treated with FOLFIRI and aflibercept in the second-line were included in the study. The clinical and pathological features of the patients were recorded retrospectively. Survival (overall and progression-free survival [PFS]), response rates, and safety data were analyzed. Results: The median age was 61. Majority of patients (87.5%) received first-line bevacizumab and 10.1% of patients received anti-epidermal growth factor receptor agents. About 80% of patients had KRAS, 18.6% of patients had NRAS, and 6.4% of patients had BRAF mutations. The median OS was 11.6 months (95% confidence interval [CI], 10.6-12.6) and the median PFS was 6 months (95% CI, 5.5-6.5). About 4.6% of patients had complete response and 30.6% of patients had partial response as best tumor response. Grade 1-2 toxicities were seen in 33.4% of patients, while grade 3-4 toxicities were recorded in 27% of patients. Eight patients (2%) died due to treatment toxicity. Conclusions: Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial. © 2022 Authors. All rights reserved.
dc.identifier.DOI-ID10.4103/jcrt.jcrt_1104_21
dc.identifier.issn09731482
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12452
dc.language.isoEnglish
dc.publisherWolters Kluwer Medknow Publications
dc.rightsAll Open Access; Gold Open Access
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBevacizumab
dc.subjectCamptothecin
dc.subjectColonic Neoplasms
dc.subjectColorectal Neoplasms
dc.subjectFluorouracil
dc.subjectHumans
dc.subjectLeucovorin
dc.subjectMiddle Aged
dc.subjectRectal Neoplasms
dc.subjectRetrospective Studies
dc.subjectaflibercept
dc.subjectantineoplastic agent
dc.subjectB Raf kinase
dc.subjectbevacizumab
dc.subjectcapecitabine plus oxaliplatin
dc.subjectcetuximab
dc.subjectepidermal growth factor receptor antibody
dc.subjectfluorouracil
dc.subjectfolinic acid
dc.subjectirinotecan
dc.subjectoxaliplatin
dc.subjectpanitumumab
dc.subjectRas protein
dc.subjectregorafenib
dc.subjectantineoplastic agent
dc.subjectbevacizumab
dc.subjectcamptothecin
dc.subjectfluorouracil
dc.subjectfolinic acid
dc.subjectadult
dc.subjectaged
dc.subjectanemia
dc.subjectArticle
dc.subjectasthenia
dc.subjectcancer combination chemotherapy
dc.subjectclinical outcome
dc.subjectclinical practice
dc.subjectdiarrhea
dc.subjectdigestive system perforation
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjectgene mutation
dc.subjecthuman
dc.subjecthypertension
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastatic colorectal cancer
dc.subjectmultiple cycle treatment
dc.subjectneutropenia
dc.subjectoncogene N ras
dc.subjectoverall survival
dc.subjectprogression free survival
dc.subjectproteinuria
dc.subjectretrospective study
dc.subjectstomatitis
dc.subjectthrombocytopenia
dc.subjectunspecified side effect
dc.subjectcolon tumor
dc.subjectcolorectal tumor
dc.subjectgenetics
dc.subjectmiddle aged
dc.subjectrectum tumor
dc.titleEfficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
dc.typeArticle

Files

Collections

Scopus Koleksiyonu